{"id":30198,"date":"2025-03-24T17:11:57","date_gmt":"2025-03-24T16:11:57","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=30198"},"modified":"2025-03-26T14:26:17","modified_gmt":"2025-03-26T13:26:17","slug":"loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/","title":{"rendered":"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb"},"content":{"rendered":"\n<p>Le 5 mars, l&#8217;OMS a publi\u00e9 un document intitul\u00e9 \u00ab The case for investment and action in infection prevention and control \u00bb (ou \u00ab arguments en faveur de l&#8217;investissement et de l&#8217;action dans la pr\u00e9vention et la lutte contre les infections \u00bb). Ce&nbsp;<a href=\"https:\/\/iris.who.int\/handle\/10665\/380704\" target=\"_blank\" rel=\"noreferrer noopener\">document<\/a>&nbsp;fournit des donn\u00e9es sur le retour sur investissement attendu et des conseils pour la mise en \u0153uvre et le suivi du plan d&#8217;action mondial de l&#8217;OMS sur la pr\u00e9vention et la lutte contre les infections, \u00e0 l\u2019\u00e9chelle nationale.<\/p>\n\n\n\n<div class=\"wp-block-columns are-vertically-aligned-bottom is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-bottom is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure data-wp-context=\"{&quot;uploadedSrc&quot;:&quot;https:\\\/\\\/ppr-antibioresistance.inserm.fr\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Capture-decran-2025-03-26-103451.png&quot;,&quot;figureClassNames&quot;:&quot;wp-block-image size-large&quot;,&quot;figureStyles&quot;:null,&quot;imgClassNames&quot;:&quot;wp-image-30211&quot;,&quot;imgStyles&quot;:null,&quot;targetWidth&quot;:751,&quot;targetHeight&quot;:1060,&quot;scaleAttr&quot;:false,&quot;ariaLabel&quot;:&quot;Agrandir l\\u2018image&quot;,&quot;alt&quot;:&quot;&quot;}\" data-wp-interactive=\"core\/image\" class=\"wp-block-image size-large wp-lightbox-container\"><img fetchpriority=\"high\" decoding=\"async\" width=\"725\" height=\"1024\" data-wp-init=\"callbacks.setButtonStyles\" data-wp-on--click=\"actions.showLightbox\" data-wp-on--load=\"callbacks.setButtonStyles\" data-wp-on-window--resize=\"callbacks.setButtonStyles\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png\" alt=\"\" class=\"wp-image-30211\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png 725w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-213x300.png 213w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451.png 751w\" sizes=\"(max-width: 725px) 100vw, 725px\" \/><button\n\t\t\tclass=\"lightbox-trigger\"\n\t\t\ttype=\"button\"\n\t\t\taria-haspopup=\"dialog\"\n\t\t\taria-label=\"Agrandir l\u2018image\"\n\t\t\tdata-wp-init=\"callbacks.initTriggerButton\"\n\t\t\tdata-wp-on--click=\"actions.showLightbox\"\n\t\t\tdata-wp-style--right=\"context.imageButtonRight\"\n\t\t\tdata-wp-style--top=\"context.imageButtonTop\"\n\t\t>\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"12\" height=\"12\" fill=\"none\" viewBox=\"0 0 12 12\">\n\t\t\t\t<path fill=\"#fff\" d=\"M2 0a2 2 0 0 0-2 2v2h1.5V2a.5.5 0 0 1 .5-.5h2V0H2Zm2 10.5H2a.5.5 0 0 1-.5-.5V8H0v2a2 2 0 0 0 2 2h2v-1.5ZM8 12v-1.5h2a.5.5 0 0 0 .5-.5V8H12v2a2 2 0 0 1-2 2H8Zm2-12a2 2 0 0 1 2 2v2h-1.5V2a.5.5 0 0 0-.5-.5H8V0h2Z\" \/>\n\t\t\t<\/svg>\n\t\t<\/button><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-bottom is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p><strong>The case for investment and action in infection prevention and control<\/strong><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-25 has-custom-font-size is-style-outline has-small-font-size\"><a class=\"wp-block-button__link has-luminous-vivid-orange-color has-text-color has-link-color wp-element-button\" href=\"https:\/\/iris.who.int\/handle\/10665\/380704\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Cliquez ici<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le 5 mars, l&#8217;OMS a publi\u00e9 un document intitul\u00e9 \u00ab The case for investment and action in infection prevention and control \u00bb (ou \u00ab arguments en faveur de l&#8217;investissement et de l&#8217;action dans la pr\u00e9vention et la lutte contre les infections \u00bb). Ce document fournit des donn\u00e9es sur le retour sur investissement attendu et des conseils pour la mise en \u0153uvre et le suivi du plan d&#8217;action mondial de l&#8217;OMS sur la pr\u00e9vention et la lutte contre les infections, \u00e0 l\u2019\u00e9chelle nationale.<\/p>\n","protected":false},"author":275,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31,26],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T16:11:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T13:26:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png\" \/>\n<meta name=\"author\" content=\"supportmlcom\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"supportmlcom\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/\"},\"author\":{\"name\":\"supportmlcom\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5\"},\"headline\":\"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb\",\"datePublished\":\"2025-03-24T16:11:57+00:00\",\"dateModified\":\"2025-03-26T13:26:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/\"},\"wordCount\":110,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png\",\"articleSection\":[\"Actualit\u00e9s\",\"Infos pratiques &amp; communications\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/\",\"name\":\"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png\",\"datePublished\":\"2025-03-24T16:11:57+00:00\",\"dateModified\":\"2025-03-26T13:26:17+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5\",\"name\":\"supportmlcom\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/","og_locale":"fr_FR","og_type":"article","og_title":"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2025-03-24T16:11:57+00:00","article_modified_time":"2025-03-26T13:26:17+00:00","og_image":[{"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png"}],"author":"supportmlcom","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"supportmlcom"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/"},"author":{"name":"supportmlcom","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5"},"headline":"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb","datePublished":"2025-03-24T16:11:57+00:00","dateModified":"2025-03-26T13:26:17+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/"},"wordCount":110,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png","articleSection":["Actualit\u00e9s","Infos pratiques &amp; communications"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/","name":"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png","datePublished":"2025-03-24T16:11:57+00:00","dateModified":"2025-03-26T13:26:17+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/03\/Capture-decran-2025-03-26-103451-725x1024.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/loms-publie-the-case-for-in-investment-and-action-in-infection-prevention-and-control\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"L\u2019OMS publie \u00ab The case for in investment and action in infection prevention and control \u00bb"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5","name":"supportmlcom"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-13 02:52:30","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/30198"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/275"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=30198"}],"version-history":[{"count":5,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/30198\/revisions"}],"predecessor-version":[{"id":30225,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/30198\/revisions\/30225"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=30198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=30198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=30198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}